Top Markets
Coin of the day
Abliva AB (publ) Abliva AB (publ)

Abliva AB (publ)

ABLI
Classement en actions #22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Prix de l'action
$0.04959193
Dernière synchronisation: 2025-03-17
Capitalisation boursière
$79.94M
Changement (1 jour)
13.49%
Changement (1 an)
0.00%
Pays
SE
Échange Abliva AB (publ) (ABLI)

Catégorie

EPS pour Abliva AB (publ) (ABLI)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Abliva AB (publ), l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Abliva AB (publ) de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH